Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.

Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE 2nd, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L.

Clin Cancer Res. 2019 Jan 1;25(1):358-368. doi: 10.1158/1078-0432.CCR-18-1211. Epub 2018 Nov 13.

PMID:
30425092
2.

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE 2nd, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L.

Oncoimmunology. 2018 Feb 21;7(6):e1434464. doi: 10.1080/2162402X.2018.1434464. eCollection 2018.

3.

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy PN, Herndon JE 2nd, McLendon RE, Keir ST, Archer GE, Reap EA, Sanchez-Perez L, Bigner DD, Sampson JH.

Clin Cancer Res. 2018 Aug 1;24(15):3611-3631. doi: 10.1158/1078-0432.CCR-17-0126. Epub 2018 Apr 27.

4.

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE 2nd, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, Hossain-Ibrahim MK, Saraswathula A, Nair SK, Dunn-Pirio AM, Broome TM, Weinhold KJ, Desjardins A, Vlahovic G, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Fecci PE, Mitchell DA, Sampson JH.

Cancer Res. 2018 Jan 1;78(1):256-264. doi: 10.1158/0008-5472.CAN-17-0469. Epub 2017 Nov 1.

5.

Structure and Dynamics Study of LeuT Using the Markov State Model and Perturbation Response Scanning Reveals Distinct Ion Induced Conformational States.

Asciutto EK, Gedeon PC, General IJ, Madura JD.

J Phys Chem B. 2016 Aug 25;120(33):8361-8. doi: 10.1021/acs.jpcb.6b02053. Epub 2016 Jun 30.

6.

Are BiTEs the "missing link" in cancer therapy?

Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, Fecci PE, Sampson JH.

Oncoimmunology. 2015 Apr 30;4(6):e1008339. eCollection 2015 Jun. Review.

7.

Epidermal growth factor receptor and variant III targeted immunotherapy.

Congdon KL, Gedeon PC, Suryadevara CM, Caruso HG, Cooper LJ, Heimberger AB, Sampson JH.

Neuro Oncol. 2014 Oct;16 Suppl 8:viii20-5. doi: 10.1093/neuonc/nou236. Review.

8.
9.

Antibody-based immunotherapy for malignant glioma.

Gedeon PC, Riccione KA, Fecci PE, Sampson JH.

Semin Oncol. 2014 Aug;41(4):496-510. doi: 10.1053/j.seminoncol.2014.06.004. Epub 2014 Jun 12. Review.

10.

Structural dynamics of the monoamine transporter homolog LeuT from accelerated conformational sampling and channel analysis.

Thomas JR, Gedeon PC, Madura JD.

Proteins. 2014 Oct;82(10):2289-302. doi: 10.1002/prot.24588. Epub 2014 May 9.

11.

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Choi BD, Gedeon PC, Herndon JE 2nd, Archer GE, Reap EA, Sanchez-Perez L, Mitchell DA, Bigner DD, Sampson JH.

Cancer Immunol Res. 2013 Sep;1(3):163. doi: 10.1158/2326-6066.CIR-13-0049.

12.

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.

Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH.

Oncoimmunology. 2013 Dec 1;2(12):e26757. Epub 2013 Oct 22.

13.

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

Choi BD, Suryadevara CM, Gedeon PC, Herndon JE 2nd, Sanchez-Perez L, Bigner DD, Sampson JH.

J Clin Neurosci. 2014 Jan;21(1):189-90. doi: 10.1016/j.jocn.2013.03.012. Epub 2013 Sep 17.

14.

An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.

Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH.

Expert Rev Clin Pharmacol. 2013 Jul;6(4):375-86. doi: 10.1586/17512433.2013.811806. Review.

15.

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH.

J Immunol Methods. 2013 Sep 30;395(1-2):14-20. doi: 10.1016/j.jim.2013.06.003. Epub 2013 Jun 24.

16.

Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.

Gedeon PC, Choi BD, Sampson JH, Bigner DD.

Drugs Future. 2013 Mar;38(3):147-155.

17.

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):270-5. doi: 10.1073/pnas.1219817110. Epub 2012 Dec 17.

18.

LeuT conformational sampling utilizing accelerated molecular dynamics and principal component analysis.

Thomas JR, Gedeon PC, Grant BJ, Madura JD.

Biophys J. 2012 Jul 3;103(1):L1-3. doi: 10.1016/j.bpj.2012.05.002.

19.

Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer.

Gedeon PC, Indarte M, Surratt CK, Madura JD.

Proteins. 2010 Mar;78(4):797-811. doi: 10.1002/prot.22601.

PMID:
19899168

Supplemental Content

Loading ...
Support Center